MAPT and Alzheimer disease: Together, the published body of TRFT clinical studies in AD subjects [13,14,30] are notable because they are the first to (1) report effects of an intervention on soluble human brain toxin levels (e.g., Aβ, tau), and (2) provide human blood biomarker evidence of increased brain cleansing by a therapeutic intervention.